<?xml version="1.0" encoding="utf-8"?>
<snippet>
  <docid>4651424791018402600</docid>
  <date>04/08/2017</date>
  <time>06:44</time>
  <isTopNews>false</isTopNews>
  <source>Courier Mail</source>
  <url>http://www.couriermail.com.au/business/breaking-news/bostons-distribution-option-lapses/news-story/593ef53556edc97c1569427379e7e987</url>
  <title>Boston's distribution option lapses</title>
  <content>
REVA Medical said Boston Scientific Corporation's exclusive right to negotiate for distribution of REVA's coronary and peripheral bioresorbable scaffolds has expired.
BSC's election window was triggered earlier this year when the company delivered an extensive set of positive clinical data supporting the performance of Fantom, the company's drug-eluting coronary scaffold.
With expiration of the distribution option, all aspects of the 2007 agreement are now concluded.
Originally published as
</content>
  <sindexList>
  <sindex>
    <name>BSC</name>
    <count>1</count>
    <score>0</score>
  </sindex>
  <sindex>
    <name>REVA Medical</name>
    <count>1</count>
    <score>2</score>
  </sindex>
  <sindex>
    <name>Fantom</name>
    <count>1</count>
    <score>4</score>
  </sindex>
  <sindex>
    <name>Boston Scientific Corporation</name>
    <count>1</count>
    <score>2</score>
  </sindex>
  <sindex>
    <name>Reva</name>
    <count>1</count>
    <score>2</score>
  </sindex>
  <sindex>
    <name>Boston</name>
    <count>1</count>
    <score>-1</score>
  </sindex>
  </sindexList>
</snippet>
